MedTrace Logo

Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study

NCT05963646 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-02-19

No results posted yet for this study

Summary

This study is a biomarker evaluation study in patients with geographic atrophy secondary to age-related macular degeneration (AMD). The study evaluates microperimetry (fundus-controlled perimetry) and optical coherence tomography imaging for assessing changes in retinal sensitivity and anatomy over time.

Conditions

  • Age-Related Macular Degeneration
  • Geographic Atrophy
  • Visual Field Defect, Central Scotoma of Both Eyes

Interventions

DIAGNOSTIC_TEST

Natural history study

Patients were monitored with a panel of visual function tests and imaging modalities. Functional tests included best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), and contrast sensitivity function evaluation (qCSF method). Imaging assessments included fundus autofluorescence, optical coherence tomography and optical coherence tomography angiography.

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Institute of Molecular and Clinical Ophthalmology Basel

    lead OTHER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-16
Primary Completion
2023-06-23
Completion
2023-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05963646 on ClinicalTrials.gov